Cargando…

Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients

INTRODUCTION: Chemotherapy-induced anemia (CIA) is a frequent complication among cancer patients, with elderly patients more likely to suffer severe effects. Biosimilar erythropoiesis-stimulating agents lower costs of supportive cancer treatment, and thus are particularly relevant in the elderly can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kurtz, Jean-Emmanuel, Soubeyran, Pierre, Michallet, Mauricette, Luporsi, Elisabeth, Albrand, Hélène
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094611/ https://www.ncbi.nlm.nih.gov/pubmed/27822071 http://dx.doi.org/10.2147/OTT.S104743

Ejemplares similares

BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study
por: Michallet, Mauricette, et al.
Publicado: (2014)

Erratum to: BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study
por: Michallet, Mauricette, et al.
Publicado: (2014)

Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained
por: Aapro, Matti, et al.
Publicado: (2018)

Evaluation of a biosimilar recombinant alpha epoetin in the management of anemia in hemodialysis patients
por: Beiraghdar, Fatemeh, et al.
Publicado: (2015)

Epoetin beta for the treatment of chemotherapy-induced anemia: an update
por: Galli, Luca, et al.
Publicado: (2015)

Quality of Original and Biosimilar Epoetin Products
por: Brinks, Vera, et al.
Publicado: (2010)

Biosimilar Retacrit(®) (epoetin zeta) in the treatment of chemotherapy-induced symptomatic anemia in hematology and oncology in Germany (ORHEO) – non-interventional study
por: Losem, Christoph, et al.
Publicado: (2017)

Recombinant human epoetin beta in the treatment of chemotherapy-related anemia
por: Macpherson, Iain RJ, et al.
Publicado: (2009)

Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?
por: Goldsmith, David, et al.
Publicado: (2018)

Critical Role of Iron in Epoetin Alfa Treatment of Chemotherapy-Associated Anemia
por: Gross, Irwin, et al.
Publicado: (2016)

Switching Between Epoetins: A Practice in Support of Biosimilar Use
por: D’Amore, Carmen, et al.
Publicado: (2016)

Cost-Minimization Analysis of Once-Weekly Versus Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia
por: Cremieux, Pierre Y., et al.
Publicado: (2004)

Recombinant human epoetin beta in the treatment of renal anemia
por: Locatelli, Francesco, et al.
Publicado: (2007)

Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study
por: Stoppa, Giovanna, et al.
Publicado: (2018)

Anti-epoetin-antibody-induced anemia in a child with chronic renal failure
por: Jöbsis, Jasper J., et al.
Publicado: (2010)

Long-term treatment with biosimilar epoetin-α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study
por: London, Gérard, et al.
Publicado: (2018)

Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease
por: Ohashi, Naro, et al.
Publicado: (2012)

Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility
por: Davis-Ajami, Mary Lynn, et al.
Publicado: (2014)

Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for the Management of Anemia in Hemodialysis Patients
por: Prasad, Bhanu, et al.
Publicado: (2020)

Effect of occasional epoetin use in combination with a stable darbepoetin dosage on anemia management in hemodialysis patients
por: Shimamatsu, Kazumasa
Publicado: (2014)

Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study
por: Belleudi, Valeria, et al.
Publicado: (2019)

Epoetin Alfa Improves Anemia and Anemia-Related, Patient-Reported Outcomes in Patients with Breast Cancer Receiving Myelotoxic Chemotherapy: Results of a European, Multicenter, Randomized, Controlled Trial
por: Pronzato, Paolo, et al.
Publicado: (2010)

Darbepoetin Versus Epoetin Alfa for the Correction of Anemia in Cancer Patients Receiving Radiotherapy or Chemoradiotherapy Treatment
por: Ots, Pilar Ma Samper, et al.
Publicado: (2008)

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation
por: Fujisaka, Y, et al.
Publicado: (2011)

Pure red cell aplasia induced by epoetin zeta
por: Panichi, Vincenzo, et al.
Publicado: (2016)

Epoetin beta pegol for treatment of anemia ameliorates deterioration of erythrocyte quality associated with chronic kidney disease
por: Aizawa, Ken, et al.
Publicado: (2018)

Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease
por: Fishbane, Steven, et al.
Publicado: (2019)

Safety and Efficacy of Methoxy Polyethylene Glycol-epoetin Beta in Anemia Treatment in Patients on Hemodialysis: a Macedonian Experience
por: Kacarska - Fotevska, Isidora Isidora, et al.
Publicado: (2020)

The Cost-Effectiveness of Using Epoetin-Beta Versus Darbepoetin-Alfa for the Treatment of Anemia Among Chronic Hemodialysis Patients
por: AlKharboush, Hanan, et al.
Publicado: (2020)

Pharmacoutilization of epoetins in naïve patients with hematological malignancies in an unselected Italian population under clinical practice setting: a comparative analysis between originator and biosimilars
por: Perrone, Valentina, et al.
Publicado: (2016)

Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy
por: McGarvey, November, et al.
Publicado: (2015)

Transplant Tolerance Induction in Newborn Infants: Mechanisms, Advantages, and Potential Strategies
por: Pan, Hua, et al.
Publicado: (2016)

Epoetin Alpha and Epoetin Zeta: A Comparative Study on Stimulation of Angiogenesis and Wound Repair in an Experimental Model of Burn Injury
por: Irrera, Natasha, et al.
Publicado: (2015)

Outcomes of Antifungal Prophylaxis in High-Risk Haematological Patients (AML under Intensive Chemotherapy): The SAPHIR Prospective Multicentre Study
por: Gangneux, Jean-Pierre, et al.
Publicado: (2020)

Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies
por: Wish, Jay B., et al.
Publicado: (2019)

Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience
por: Heiblig, Maël, et al.
Publicado: (2019)

The Use of Epoetin-α in Revision Knee Arthroplasty
por: Delasotta, Lawrence A., et al.
Publicado: (2012)

Epoetin Theta in Anaemic Cancer Patients Receiving Platinum-Based Chemotherapy: A Randomised Controlled Trial
por: Tjulandin, Sergei A, et al.
Publicado: (2010)

Adding Epoetin Alfa to Intense Dose-Dense Adjuvant Chemotherapy for Breast Cancer: Randomized Clinical Trial
por: Moebus, Volker, et al.
Publicado: (2013)

Toward confirmation of the safety and efficacy of methoxy polyethylene glycol-epoetin beta in anemia treatment in patients on hemodialysis: a Macedonian experience
por: Kacarska-Fotevska, Isidora, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_klp2f73m78sku63278jmsgre53